INTEX NOLVA-20

$52.50

INTEX NOLVA-20 is not a steroid, rather a selective estrogen blocker. While Tamoxifen Citrate doesn’t prevent the buildup of estrogen in the body, it does prevent it from acting on certain receptors, most notably, those located in the nipples. This has obvious benefits to bodybuilders, because this is the area in which “gyno” occurs during […]

Category:

Description

INTEX NOLVA-20 is not a steroid, rather a selective estrogen blocker. While Tamoxifen Citrate doesn’t prevent the buildup of estrogen in the body, it does prevent it from acting on certain receptors, most notably, those located in the nipples. This has obvious benefits to bodybuilders, because this is the area in which “gyno” occurs during the use of aromatizing steroids such as testosterone.

INTEX NOLVA-20 also offers another great benefit to bodybuilders due to the fact that it can greatly increase the amount of testosterone that the body makes by stimulating LH production. This makes the drug a great choice for PCT.

While INTEX NOLVA-20 has obvious benefits concerning estrogen buildup in the body, it is important to note that it can have adverse effects towards progesterone related steroids. Because of this, it’s recommended that bodybuilders don’t use INTEX NOLVA-20 in conjunction with steroids such as Deca or Trenbolone.

It’s also important to note that INTEX NOLVA-20 doesn’t reduce estrogen throughout the body, and that those athletes looking to minimize overall water retention and bloat should look towards true estrogen blockers such as Anastrozole or Exemestane.

Bodybuilders often use INTEX NOLVA-20 in doses of 25-75 mg a day throughout cycle duration where gyno is a concern. Those looking to incorporate INTEX NOLVA-20 into their PCT program will typically run the substance at similar doses for 4-6 upon the discontinued use of all steroids. Users may also choose to add Proviron and/or HCG to their PCT protocol.

Reviews

There are no reviews yet.

Be the first to review “INTEX NOLVA-20”

Your email address will not be published. Required fields are marked *